Biolargo (BLGO) director receives stock options instead of $15,000 board fees

Rhea-AI Filing Summary

BIOLARGO, INC. director Jack B. Strommen received an option grant as part of his board compensation. He was granted options to purchase 132,159 shares of common stock at an exercise price of $0.1135 per share, expiring on June 30, 2036. After this grant, he holds options to purchase a total of 2,584,262 shares. The grant was issued in lieu of $15,000 in fees for his most recently completed quarterly board service under the company’s 2024 Equity Incentive Plan.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider STROMMEN JACK B.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Option to Purchase Common Stock	132,159	$0.00	--

Holdings After Transaction: Option to Purchase Common Stock — 2,584,262 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 132,159 shares Exercise price: $0.1135 per share Total options after grant: 2,584,262 shares +2 more

5 metrics

Option grant size 132,159 shares Options to purchase common stock granted on June 30, 2026

Exercise price $0.1135 per share Strike price for the granted options

Total options after grant 2,584,262 shares Options to purchase common stock following this transaction

Board fees paid in equity $15,000 Quarterly board service fees satisfied via option grant

Option expiration June 30, 2036 Expiration date of the granted options

Key Terms

Option to Purchase Common Stock, exercise price, 2024 Equity Incentive Plan, board of directors

4 terms

Option to Purchase Common Stock financial

"security_title: Option to Purchase Common Stock"

exercise price financial

"equal to the amount of fees due divided by the exercise price of the Option"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

2024 Equity Incentive Plan financial

"pursuant to the Issuer's 2024 Equity Incentive Plan"

board of directors financial

"in exchange for services on its board of directors for the most recently completed quarterly period"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 07:42 PM Accepted by SEC EDGAR 07/02/2026 - 07:41 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

STROMMEN JACK B.

(Last) (First) (Middle)

7108 31ST AVENUE NORTH

(Street)

MINNEAPOLIS MINNESOTA 55427

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOLARGO, INC. [ BLGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$0.1135	06/30/2026		A		132,159		06/30/2026	06/30/2036	Common Stock	132,159	(1)	2,584,262	D

Explanation of Responses:

1. This Option was issued to Reporting Person as payment for $15,000 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan. The number of shares in the Option is equal to the amount of fees due divided by the exercise price of the Option.

	/s/ John R. Browning, attorney-in-fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did BIOLARGO (BLGO) director Jack B. Strommen report in this Form 4?

Director Jack B. Strommen reported receiving an option grant to purchase 132,159 shares of BIOLARGO common stock. The options were granted as compensation for quarterly board service fees under the 2024 Equity Incentive Plan, not as an open-market stock purchase.

How many BIOLARGO (BLGO) shares can Jack B. Strommen acquire under the new option grant?

The new grant allows Jack B. Strommen to acquire 132,159 shares of BIOLARGO common stock. These are derivative securities (options), meaning he can choose to exercise them in the future at the stated exercise price rather than owning the shares immediately.

What is the exercise price and expiration date of Jack B. Strommen’s BIOLARGO options?

The options have an exercise price of $0.1135 per share and expire on June 30, 2036. This gives Strommen a long-dated right to purchase BIOLARGO shares at that fixed price if he chooses to exercise before expiration.

How many BIOLARGO option shares does Jack B. Strommen hold after this transaction?

After this grant, Jack B. Strommen holds options to purchase 2,584,262 shares of BIOLARGO common stock. This figure reflects his total option position reported in the filing, including the newly awarded 132,159-share option grant.

Was Jack B. Strommen’s BIOLARGO option grant paid in cash or equity?

The compensation was paid in equity via an option grant rather than cash. The filing states the option was issued as payment for $15,000 in fees due for his most recently completed quarterly board service, using the 2024 Equity Incentive Plan.